Auranofin

This classification denotes an immunosuppressant with the molecular formula C20H34AuO9PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3H04W2810V, chemically known as gold, (2,3,4, 6-tetra-o-acetyl-1-thio-.beta.-d-glucopyranosato-s)(triethylphosph ine)- but more generally known as auranofin, which bears US NIH Compound Identifier 6333901. European Medicines Agency schedules Auranofin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05610MIG. The term AURANOFIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules auranofin in its Anatomical Therapeutic Chemical (ATC) Classification. AURANOFIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule auranofin under HS 28433000 and SITC 52432. As of Q4 2014, AURANOFIN remains US FDA's Preferred Term for this commodity. Auranofin bears US NLM identifiers UMLS ID C0699923 and NCI Concept Code C65242. SMILES: [AU](SC1OC(C(OC(=O)C)C(OC(=O)C)C1OC(=O)C)COC(=O)C)P(CC)(CC)CC.